Retrospective analysis of SGLT2 inhibitors in heart failure with preserved ejection fraction
Abstract Aims Heart failure (HF) is one of the leading causes of cardiovascular morbidity and mortality. HF with preserved ejection fraction (HFpEF), or diastolic failure, accounts for half of all HF cases and differs from HF with reduced ejection fraction (HFrEF). Patients with HFpEF are typically...
Main Authors: | John S. Clemmer, Taylor J. Ward, Seth T. Lirette |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2023-06-01
|
Series: | ESC Heart Failure |
Subjects: | |
Online Access: | https://doi.org/10.1002/ehf2.14347 |
Similar Items
-
Heart Failure with Preserved Ejection Fraction (HFpEF): Part 2 Review of Experience and Evidence with SGLT-2 Inhibitors and Commentary
by: Soneil Guptha, Eteri Tsetskhladze
Published: (2023-06-01) -
Emerging concepts in heart failure treatment and management: focus on SGLT2 inhibitors in heart failure with preserved ejection fraction
by: Andrea Beatriz De Lorenzi, et al.
Published: (2023-01-01) -
Heart failure with preserved ejection fraction – onset
by: Branimir Kanazirev
Published: (2021-07-01) -
Heart failure with preserved ejection fraction and atrial fibrillation: recent advances and open questions
by: Laurent Fauchier, et al.
Published: (2023-02-01) -
Prevalence and prognosis of frailty in older patients with stage B heart failure with preserved ejection fraction
by: Chen Meng, et al.
Published: (2023-04-01)